U.S. markets close in 4 hours 46 minutes

Soliton, Inc. (SOLY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
13.31-0.24 (-1.77%)
As of 10:58AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close13.55
Open13.55
Bid13.17 x 900
Ask13.47 x 1000
Day's Range13.03 - 13.55
52 Week Range5.69 - 15.50
Volume33,720
Avg. Volume352,086
Market Cap282.038M
Beta (5Y Monthly)0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.74
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Soliton Selects RESONICâ„¢ As Brand Name for FDA-Cleared Rapid Acoustic Pulse Device
    PR Newswire

    Soliton Selects RESONICâ„¢ As Brand Name for FDA-Cleared Rapid Acoustic Pulse Device

    Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that it has selected RESONICâ„¢ as the brand name for the Rapid Acoustic Pulse (RAP) Device.

  • Soliton Announces RAP Treatment Reduces Effects of Liver Fibrosis by 42% in Animal Study
    PR Newswire

    Soliton Announces RAP Treatment Reduces Effects of Liver Fibrosis by 42% in Animal Study

    Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced that a pre-clinical study in animals demonstrated positive results for the potential treatment of liver fibrosis. Validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse ("RAP") therapy reduced the effects of induced liver fibrosis 7-days following completion of carbon tetrachloride (CCL4) induction by 42%. In addition, post treatment histology slides stained with picrosirius red (PSR) showed a lower percentage of fibrosis from a single 2-minute RAP treatment compared to the Control group.

  • Soliton to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
    PR Newswire

    Soliton to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

    Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 4, 2021, after the market closes.